Delving into the Latest Updates on Biotin with Synapse

Overview

Basic Info

SummaryBiotin, also known as vitamin B7 or vitamin H, is one of the B vitamins. It is essential for the metabolism of carbohydrates, fats, and proteins. Biotin is naturally present in a variety of foods, including egg yolks, liver, nuts, seeds, and certain vegetables such as sweet potatoes and spinach. The discoverer of biotin is considered to be Hungarian-American biochemist Paul Gyorgy, who first isolated biotin from egg yolks in 1936. Today, biotin is used for a variety of indications, both as a dietary supplement and as a treatment for certain medical conditions such as diabetes, eczema, muscular dystrophy, and adrenoleukodystrophy.

Drug Type

Small molecule drug

Synonyms

(+)-cis-Hexahydro-2-oxo-1H-thieno[3,4]imidazole-4-valeric acid, (3aS,4S,6aR)-Hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-valeric acid, 5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic acid

+ [16]

Target

ABCD1

Action

inhibitors

Mechanism

ABCD1 inhibitors(ATP Binding Cassette Subfamily D Member 1 inhibitors)

Therapeutic Areas

Endocrinology and Metabolic DiseaseSkin and Musculoskeletal DiseasesNervous System Diseases+ [2]

Active Indication

Diabetes MellitusEczemaAlzheimer Disease+ [2]

Inactive Indication

Amyotrophic Lateral SclerosisCharcot-Marie-Tooth Disease, Type IaCharcot-Marie-Tooth Disease, Type Ib+ [7]

Originator Organization-

Active Organization

Harvard Medical SchoolCiberer

IDIBELL - Bellvitge Biomedical Research Institute

+ [1]

Inactive Organization

MedDay Pharmaceuticals SA

Drug Highest PhaseApproved

First Approval Date-

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC10H16N2O3S

InChIKeyYBJHBAHKTGYVGT-ZKWXMUAHSA-N

CAS Registry58-85-5

Switchable supramol. photosensitizers have the potential to be more potent and decrease common side effects of photodynamic therapy such as patient′s sensitivity to ambient light.Combining this supramol. strategy with a cancer-targeting strategy would also improve selectivity towards tumoral cells.In this work, we take advantage of the strong binding ability of cucurbit[8]uril towards cationic photosensitizer methylene blue.Encapsulation of two mols. of methylene blue inside the cavity of cucurbit[8]uril leads to strong quenching of its photoactivity, particularly the generation of singlet oxygen.In order to release selectively the photosensitizer, we synthesized a new memantine-biotin conjugate that is able to cross a liposomal bilayer as a model for a biol. membrane and bind to cucurbit[8]uril releasing the photosensitizer.This phenomenon leads to a sizable boost in singlet oxygen generation.In vitro phototoxicity studies in tumoral cells show a significant difference in cell killing after the addition of the memantine-biotin displacing agent.These studies have important potential for more selective photodynamic therapy of cancer.

01 May 2025·TALANTA

Cell-free transcription amplification-based split-type electrochemical sensor using enzyme-linked magnetic microbeads for minimal residual leukemia detection

Article

Author: Zhang, Chui-Ju ; Lin, Xin-Hua ; Zhong, Guang-Xian ; Yang, Liang-Yong ; Chen, Jin-Yuan ; Lin, Huang-Feng ; Weng, Huan-Jiao ; Yu, Lu-Ying ; Lin, Ji-Zhen

Constrained by detecting techniques, patients with acute promyelocytic leukemia (APL) are often confronted with minimal residual disease (MRD) and a high risk of relapse. Thus, a pragmatic and robust method for MRD monitoring is urgently needed. Herein, a novel split-type electrochemical sensor (E-sensor) was developed by integrating nucleic acid sequence-based amplification (NASBA) with enzyme-linked magnetic microbeads (MMBs) for ultra-sensitive detection of the PML/RARα transcript. In this system, NASBA facilitated efficient amplification under isothermal conditions, generating a large amount of RNA amplicons, which mediated the quick binding between horseradish peroxidase (HRP) and MMBs. The separately HRP-linked MMBs were subsequently transferred onto the surface of magnetic glass carbon electrode, producing a remarkably strong electrochemical signal in the presence of the HRP substrate. The proposed split-type E-sensor could detect the PML/RARα transcript with a high sensitivity (a limit detection of 100 aM), a high specificity (single base discrimination) as well as a high stability (a relative standard deviation of 8.3 % for 10 fM target RNA and 6.0 % for 100 fM target RNA). Finally, it could achieve both direct detection of serum cell-free RNA and specific intracellular RNA detection. Owing to its isothermal characteristics, robustness, and suitability for point-of-care testing, this method offers a powerful tool for the early diagnosis of APL and the monitoring of MRD, which holds a great significance for facilitating treatment response assessment and making treatment decisions.

01 May 2025·BIOMATERIALS

Myocardial delivery of miR30d with peptide-functionalized milk-derived extracellular vesicles for targeted treatment of hypertrophic heart failure

Article

Author: Yi, Huaxi ; Yin, Wenchao ; Xu, Jiarun ; Zhang, Yameng ; Lai, Fengling ; Wang, Qiyue ; Zhang, Sitong ; Yin, Jie ; Wang, Jiong-Wei ; Wang, Zhaoyang ; Huang, Rong ; Wei, Guoyue ; Tong, Lingjun ; Xu, Tao ; Storm, Gert

miR30d has been shown to reverse cardiac hypertrophy. However, effective delivery of miR30d to the heart is challenging. Here, we engineered milk-derived extracellular vesicles (mEVs) by surface functionalization with an ischemic myocardium-targeting peptide (IMTP) and encapsulated miR30d to develop a formulation, the miR30d-mEVs^IMTP, enabling targeted delivery of miR30d to the injured heart. In vitro, the miR30d-mEVs^IMTP can be effectively internalized by hypoxia-induced H9C2 cells via the endo-lysosomal pathway. In the isoproterenol (ISO)-induced cardiac hypertrophy mice, more miR30d-mEVs^IMTP accumulated in cardiac tissue than miR30d-mEVs following intravenous administration. As a result, miR30d-mEVs^IMTP alleviated cardiac hypertrophy and rescued cardiac function in three murine models of hypertrophic heart failure. Mechanistically, we identified GRK5 as an unprecedented target of miR30d in cardiac hypertrophy. Taken together, our findings demonstrate that mEVs conjugated with IMTP effectively deliver miR30d to the pathological heart and thereby ameliorating cardiac hypertrophy and dysfunction via targeting GRK5-mediated signaling pathways.

11

News (Medical) associated with Biotin

17 Jun 2024

·www.sciencedaily.com

Treating the gut-brain connection with B vitamins to treat Parkinson's Disease

A study has revealed a link between gut microbiota and Parkinson's disease. The researchers discovered a decrease in bacterial genes related to the synthesis of vitamins B2 and B7. The lack of these genes was associated with reduced intestinal short-chain fatty acids and polyamines, agents that maintain the intestinal barrier and prevent the leakage of toxins into the blood that can then access the brain. Using B vitamin therapy to address these deficiencies may restore the barrier and treat Parkinson's disease. A study led by Nagoya University Graduate School of Medicine in Japan has revealed a link between gut microbiota and Parkinson's disease (PD). The researchers found a reduction in the gut bacteria of genes responsible for synthesizing the essential B vitamins B2 and B7. They also identified a relationship between the lack of these genes and low levels of agents that help maintain the integrity of the intestinal barrier. This barrier prevents toxins from entering the bloodstream, which causes the inflammation seen in PD. Their findings, published in npj Parkinson's Disease, suggest that treatment with B vitamins to address these deficiencies can be used to treat PD. PD is characterized by a variety of physical symptoms that hinder daily activities and mobility, such as shaking, slow movement, stiffness, and balance problems. While the frequency of PD may vary between different populations, it is estimated to affect approximately 1-2% of individuals aged 55 years or older. Various physiological processes are heavily influenced by the microorganisms found in the gut, which are collectively known as gut microbiota. In ideal conditions, gut microbiota produce SCFAs and polyamines, which maintain the intestinal barrier that prevents toxins entering the bloodstream. Toxins in the blood can be carried to the brain where they cause inflammation and affect neurotransmission processes that are critical for maintaining mental health. To better understand the relationship between the microbial characteristics of the gut in PD, Hiroshi Nishiwaki and Jun Ueyama from the Nagoya University Graduate School of Medicine conducted a metanalysis of stool samples from patients with PD from Japan, the United States, Germany, China, and Taiwan. They used shotgun sequencing, a technique that sequences all genetic material in a sample. This is an invaluable tool because it offers researchers a better understanding of the microbial community and genetic makeup of the sample. They observed a decrease in the bacterial genes responsible for the synthesizing of riboflavin (vitamin B2) and biotin (vitamin B7) in patients diagnosed with PD. Riboflavin and biotin, derived from both food and gut microbiota, have anti-inflammatory properties, which may counteract the neuroinflammation seen in diseases like PD. B vitamins play crucial roles in the metabolic processes that influence the production and functions of short-chain fatty acids (SCFAs) and polyamines, two agents that help maintain the integrity of the intestinal barrier, preventing toxins entering the bloodstream. An examination of fecal metabolites revealed decreases of both in patients with PD. The findings indicate a potential explanation for the progression of PD. "Deficiencies in polyamines and SCFAs could lead to thinning of the intestinal mucus layer, increasing intestinal permeability, both of which have been observed in PD," Nishiwaki explained. "This higher permeability exposes nerves to toxins, contributing to abnormal aggregation of alpha-synuclein, activating the immune cells in the brain, and leading to long-term inflammation." He added, "Supplementation therapy targeting riboflavin and biotin holds promise as a potential therapeutic avenue for alleviating PD symptoms and slowing disease progression." The results of the study highlight the importance of understanding the complex relationship among gut microbiota, metabolic pathways, and neurodegeneration. In the coming years, therapy could potentially be customized based on the unique microbiome pro each patient. By altering bacterial levels in the microbiome, doctors can potentially delay the onset of symptoms associated with diseases like PD. "We could perform gut microbiota analysis on patients or conduct fecal metabolite analysis," Nishiwaki said. "Using these findings, we could identify individuals with specific deficiencies and administer oral riboflavin and biotin supplements to those with decreased levels, potentially creating an effective treatment."

Microbial therapy

12 Mar 2024

·www.prnewswire.com

Bizz Energy Can Help Build Muscle and Boost Metabolism

The Nutrition-Filled Beverage Is Rewriting the Script When It Comes to Energy Drinks FORT LAUDERDALE, Fla., March 12, 2024 /PRNewswire/ -- Traditional energy beverages have a negative reputation for unhealthy ingredients and sugary crashes. Bizz Energy was designed to be the ultimate zero-sugar energy drink. The healthy alternative to the classic concept was developed by a team led by entrepreneur Gavin Jacono. Part of the goal with Bizz Energy is to provide a potent dose of clean, sugar-free, crashless energy. However, Jacono and his team have gone above and beyond to ensure that the nutritional elements of their formula deliver more than a punchy pick-me-up. "Part of the point with Bizz Energy has always been to be a clean energy drink option," explains Jacono. "We want health-conscious individuals to be able to use it as a way to tap energy without compromising their health in the process. But our goal from day one was much bigger than that. We wanted a drink that could enhance performance on a nutritional level. We wanted something that brought together the ideas of an energy drink and a supplement." The first step in achieving this was to avoid classic sweet tooth ingredients, like sugar, high fructose corn syrup, and even aspartame. In addition, the group avoided any harmful chemicals or additives. When it came to the energy part of the process, the R&D team managed to create a unique form of soluble Turkesterone. The natural ecdysteroid has a reputation for stimulating physical and mental energy. This works alongside a punchy per-can dose of 200mg of caffeine anhydrous. Jacono's team also looked for ingredients that could provide a net nutritional positive to the consumer. They included ingredients like creatine and essential amino acids to help with muscle growth and protein synthesis. They also included Niacin and Biotin to support an active metabolism. In the end, the Bizz Energy formula is much more than an average energy drink — or even an improved one. It functions as a dual energy booster and supplement. It can supercharge the mind, energize the body, improve physical performance, and enhance whatever mental or physical activity an individual is attempting to accomplish. Bizz Energy is a refreshing new take on a classic concept. It is a clean, crashless, and nutritious energy drink built to help people reach their goals and go the distance. A bout Bizz Energy Bizz Energy was founded by Gavin Jacono. The fitness and nutrition fanatic hails from New York City and is obsessed with boxing, weightlifting, and soccer. As an aspiring 17-year-old entrepreneur, Jacono launched Bizz Energy as a way to create the ultimate energy drink he had always wanted to fuel his athletic pursuits. Along with a potent dose of caffeine, the Bizz Energy formula taps into a unique form of soluble Turkesterone. It is delicious, clean, and effective. Learn more at bizzenergy.com. Contact: Gavin Jacono 516-637-8701 374108@email4pr.com SOURCE Bizz Energy

20 Nov 2023

·www.prnewswire.com

Designs for Health Launches Two Collagen Formulas, Whole Beauty Collagen™ & Collagen + MCT

Leading supplement brand now offers three unique researched-back collagen products PALM COAST, Fla., Nov. 20, 2023 /PRNewswire/ -- Designs for Health, the expert-recommended and preferred brand for high-quality, professional strength, research-backed supplements, and recipient of the 2023 Top Supplement Manufacturing Company award ** today announced the launch of Whole Beauty Collagen™ and Collagen + MCT. These products complement the company's bestselling Whole Body Collagen, now offering consumers three superior, efficacious collagen formulas. Whole Beauty Collagen™ is a convenient once-daily powder featuring hydrolyzed collagen peptides and Lustriva®, a patented, clinically researched blend of stabilized biotin and silica, to provide comprehensive support for hair, skin, and nails.* Evidence suggests that Lustriva® may help promote hair fullness, optimal skin texture, and nail strength.* Additionally, the magnesium biotinate used in this formula may have 40 times greater dissolvability and absorption than the biotin used in common beauty products. Collagen + MCT is a keto-friendly powder featuring hydrolyzed collagen peptides from grass-fed, pasture-raised bovine sources and medium-chain triglycerides (C8 & C10 MCTs) from highly refined coconut oil. MCTs metabolize differently than other fats; the body converts them into ketones, even when not on a ketogenic diet, and provide a quick source of energy that most cells and tissues can use. They are especially known for fueling the brain, heart, and skeletal muscles. Research also suggests that MCTs may provide fuel for brain cells, helping to support cognitive function and mental clarity.* Whole Body Collagen is a synergistic formulation designed to benefit the health of bones, joints, and skin.* It contains the research-backed collagen peptide blends Verisol®, Fortigel®, and Fortibone® derived from specific dietary collagen proteins and produced with proprietary hydrolyzation technologies to optimize their beneficial properties. This unique blend is supported by clinical research showing its efficacy for collagen production, bone strength, joint health and integrity, and skin elasticity.* "While the market for collagen supplements has skyrocketed in recent years, all collagen products are not created equal, which is why we are proud to offer three high-quality research-backed formulations that consumers and practitioners can trust," said Chief Medical Officer, Dr. David M. Brady at Designs for Health. "Collagen makes up roughly 30% of the body's protein and 75% of the skin's structure; however, we start to produce less of it as we age, making supplementation vital to helping the body rebuild the collagen that it depends on. Our three unique SKUs have been carefully formulated to provide adults with an easy and convenient way to incorporate specific molecular weight clinically studied collagen into their daily wellness routines at any age." Designs for Health began in 1989 as a small educational services company with deep roots in natural medicine – and big ambitions to revolutionize the industry. More than 30 years later, the company is pioneering new approaches to nutritional science, breaking barriers in quality standards, and ultimately transforming the healthcare ecosystem. Through a robust product pipeline and a diverse portfolio of more than 300 nutritional products, Designs for Health is leading the charge in the natural and integrative medicine movement to design a well world for all. Whole Beauty Collagen, Collagen + MCT, and Whole Body Collagen are unflavored and unsweetened, making them easy to add to any beverage or shake. They are gluten-free, dairy-free, soy-free, and non-GMO, and available to purchase at . To learn more about Designs for Health and its comprehensive portfolio of products, including its line of oral health products, visit . Please tune in to Designs for Health's new podcast, Conversations for Health, and immerse yourself in the current landscape of Functional Medicine to empower you to design a well world with us. About Designs for Health, Inc. Family-owned Designs for Health, Inc. offers high-quality dietary supplements and functional foods to healthcare professionals and their patients. Guided by its founding philosophy of "Science-First™," the company holds an unwavering commitment to creating research-driven formulations with meaningful quantities of functional ingredients that maximize the potential for successful health outcomes. For over 30 years, Designs for Health has been many healthcare professionals' trusted source for not only product innovation but also leadership in clinical education and practice development solutions. **Awarded by Food Business Review *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Contact: 5WPR 212-999-5585 [email protected] SOURCE Designs for Health

100 Deals associated with Biotin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00029	Biotin	A11HA05	DB00121

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus	-	-	-
Eczema	-	-	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Sclerosis	NDA/BLA	European Union	MedDay Pharmaceuticals SA	-
Adrenoleukodystrophy	Phase 3	France	MedDay Pharmaceuticals SA	01 Oct 2014
Adrenoleukodystrophy	Phase 3	Germany	MedDay Pharmaceuticals SA	01 Oct 2014
Adrenoleukodystrophy	Phase 3	Spain	MedDay Pharmaceuticals SA	01 Oct 2014
Multiple Sclerosis, Chronic Progressive	Phase 3	France	MedDay Pharmaceuticals SA	01 Oct 2013
Optic Neuritis	Phase 3	France	MedDay Pharmaceuticals SA	01 Oct 2013
Optic Neuritis	Phase 3	United Kingdom	MedDay Pharmaceuticals SA	01 Oct 2013
Vision, Low	Phase 3	France	MedDay Pharmaceuticals SA	01 Oct 2013
Vision, Low	Phase 3	United Kingdom	MedDay Pharmaceuticals SA	01 Oct 2013
Charcot-Marie-Tooth Disease, Type Ia	Phase 2	France	MedDay Pharmaceuticals SA	05 Dec 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ENDO2024	Not Applicable	Hyperandrogenism	-	Biotin	ychlusncxy(gfurjhklod) = yfqrpqeksi emctkgpawj (egcrfngjrx ) View more	-	01 Jun 2024
EADV2023	Not Applicable	-	61	Oral biotin	mmbrdjvbhy(wojvqkbass) = wonaksnbqp idvgtxdxsx (tnwdacbycv ) View more	Positive	11 Oct 2023
EADV2023	Not Applicable	-	61	Pyridoxine	mmbrdjvbhy(wojvqkbass) = kkwvjvodnt idvgtxdxsx (tnwdacbycv ) View more	Positive	11 Oct 2023
SSIEM2023	Not Applicable	Congenital Disorders of Glycosylation biotinidase activity	29	biotin	wrufdldzee(fsxnwbbzwn) = fjbjrettel ktlaeyguuw (lgzzmydokw )	-	30 Aug 2023
PMON224 (ENDO2022)	Not Applicable	-	-	Biotin	fmceavdldg(aykoriydwf) = nfwnuykzhq efffprpqsg (kpsymrldsm )	-	01 Nov 2022
AAN2022	Not Applicable	Multiple Sclerosis	889	High-dose biotin (HDB)	dhkhyejece(kvqknlrvjo) = Thirty-one patients (4.7%) in the HDB group were found to have laboratory test interference feoglvrjly (lofncfbvdn )	-	03 May 2022
ENDO2021	Not Applicable	Adrenal Insufficiency ACTH \| morning cortisol \| DHEA-S	-	Hydrocortisone therapy	rzlygvcwhw(jmzgqjxrsm) = vxhhdkvjwh qvfqvfkodc (issxfyipka, 7.2–63.3)	-	03 May 2021
NCT02936037 (SPI2, Pubmed) Manual	Phase 3	Multiple Sclerosis, Chronic Progressive	642	MD1003	suteybxzpv(pbietyuxpp) = mrgnqukryl zlguwlkbsn (fyhkpbnaab ) View more	Negative	01 Dec 2020
NCT02936037 (SPI2, Pubmed) Manual	Phase 3	Multiple Sclerosis, Chronic Progressive	642	Placebo	suteybxzpv(pbietyuxpp) = giovrextrs zlguwlkbsn (fyhkpbnaab ) View more	Negative	01 Dec 2020
NCT02936037 (SPI2, CTgov)	Phase 3	Multiple Sclerosis, Chronic Progressive	642	PLACEBO (GROUP 1)	djluchkswi(bfhikbftqs) = qxglgdicij acrzlibqfd (avcjnzqwwa, msdpvvfszc - mkddezfapx) View more	-	23 Nov 2020
NCT02936037 (SPI2, CTgov)	Phase 3	Multiple Sclerosis, Chronic Progressive	642	MD1003 100mg capsule (GROUP 2)	djluchkswi(bfhikbftqs) = vdplrbrqhi acrzlibqfd (avcjnzqwwa, gdhwahmagp - yeinzfwwyg) View more	-	23 Nov 2020
NCT02967679 (CTgov)	Phase 2	Charcot-Marie-Tooth Disease, Type Ia \| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating \| Central Nervous System Diseases ... View more	15	MD1003	ssjpxjrpfb(qazndtavkc) = rrnphiuyvo ugqsufhgxr (dojogxjadr, 11.45) View more	-	02 Nov 2020
NCT04223232 (CTgov)	Phase 1	-	6	[14C]-MD1003	ckkakumsst(zhoudczool) = krqwmeabvf tccxzvrhbu (uvlwdblatk, 16.9) View more	-	02 Nov 2020